Literature DB >> 24022140

First Axl inhibitor enters clinical trials.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24022140     DOI： 10.1038/nbt0913-775a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  TAM receptors are pleiotropic inhibitors of the innate immune response.

Authors:  Carla V Rothlin; Sourav Ghosh; Elina I Zuniga; Michael B A Oldstone; Greg Lemke
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

2.  Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.

Authors:  Ju Han; Rui Tian; Bicheng Yong; Canqiao Luo; Pingxian Tan; Jingnan Shen; Tingsheng Peng
Journal:  Biochem Biophys Res Commun       Date:  2013-05-15       Impact factor: 3.575

3.  R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

Authors:  Sacha J Holland; Alison Pan; Christian Franci; Yuanming Hu; Betty Chang; Weiqun Li; Matt Duan; Allan Torneros; Jiaxin Yu; Thilo J Heckrodt; Jing Zhang; Pingyu Ding; Ayodele Apatira; Joanne Chua; Ralf Brandt; Polly Pine; Dane Goff; Rajinder Singh; Donald G Payan; Yasumichi Hitoshi
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

4.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.

Authors:  Christine Gjerdrum; Crina Tiron; Torill Høiby; Ingunn Stefansson; Hallvard Haugen; Tone Sandal; Karin Collett; Shan Li; Emmet McCormack; Bjørn Tore Gjertsen; David R Micklem; Lars A Akslen; Carlotta Glackin; James B Lorens
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

5.  Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer.

Authors:  Lidia Bosurgi; Jochem H Bernink; Victor Delgado Cuevas; Nicola Gagliani; Leonel Joannas; Edward T Schmid; Carmen J Booth; Sourav Ghosh; Carla V Rothlin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

6.  Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.

Authors:  Markus Hutterer; Pjotr Knyazev; Ariane Abate; Markus Reschke; Hans Maier; Nadia Stefanova; Tatjana Knyazeva; Verena Barbieri; Markus Reindl; Armin Muigg; Herwig Kostron; Guenther Stockhammer; Axel Ullrich
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

7.  Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Authors:  Zhenfeng Zhang; Jae Cheol Lee; Luping Lin; Victor Olivas; Valerie Au; Thomas LaFramboise; Mohamed Abdel-Rahman; Xiaoqi Wang; Alan D Levine; Jin Kyung Rho; Yun Jung Choi; Chang-Min Choi; Sang-We Kim; Se Jin Jang; Young Soo Park; Woo Sung Kim; Dae Ho Lee; Jung-Shin Lee; Vincent A Miller; Maria Arcila; Marc Ladanyi; Philicia Moonsamy; Charles Sawyers; Titus J Boggon; Patrick C Ma; Carlota Costa; Miquel Taron; Rafael Rosell; Balazs Halmos; Trever G Bivona
Journal:  Nat Genet       Date:  2012-07-01       Impact factor: 38.330
  7 in total
  58 in total

1.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

2.  Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.

Authors:  Cristina Bárcena; Milica Stefanovic; Anna Tutusaus; Leonel Joannas; Anghara Menéndez; Carmen García-Ruiz; Pau Sancho-Bru; Montserrat Marí; Joan Caballeria; Carla V Rothlin; José C Fernández-Checa; Pablo García de Frutos; Albert Morales
Journal:  J Hepatol       Date:  2015-04-20       Impact factor: 25.083

3.  Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.

Authors:  I-K Park; B Mundy-Bosse; S P Whitman; X Zhang; S L Warner; D J Bearss; W Blum; G Marcucci; M A Caligiuri
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

Review 4.  Molecular pathways: niches in metastatic dormancy.

Authors:  Kenji Yumoto; Matthew R Eber; Janice E Berry; Russell S Taichman; Yusuke Shiozawa
Journal:  Clin Cancer Res       Date:  2014-04-22       Impact factor: 12.531

Review 5.  Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.

Authors:  Carla V Rothlin; Jonathan A Leighton; Sourav Ghosh
Journal:  Inflamm Bowel Dis       Date:  2014-08       Impact factor: 5.325

6.  Imaging Axl expression in pancreatic and prostate cancer xenografts.

Authors:  Sridhar Nimmagadda; Mrudula Pullambhatla; Ala Lisok; Chaoxin Hu; Anirban Maitra; Martin G Pomper
Journal:  Biochem Biophys Res Commun       Date:  2013-12-11       Impact factor: 3.575

7.  Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration.

Authors:  Yanting Duan; Bo Hu; Chunxia Qiao; Longlong Luo; Xinying Li; Jing Wang; Hao Liu; Tingting Zhou; Beifen Shen; Ming Lv; Jiannan Feng
Journal:  Oncol Lett       Date:  2019-04-15       Impact factor: 2.967

8.  The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.

Authors:  Ketan S Gajiwala; Neil Grodsky; Ben Bolaños; Junli Feng; RoseAnn Ferre; Sergei Timofeevski; Meirong Xu; Brion W Murray; Ted W Johnson; Al Stewart
Journal:  J Biol Chem       Date:  2017-07-19       Impact factor: 5.157

9.  Function of Axl receptor tyrosine kinase in non-small cell lung cancer.

Authors:  Guoan Zhang; Meng Wang; Hongli Zhao; Wen Cui
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

10.  Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.

Authors:  Erinn B Rankin; Katherine C Fuh; Laura Castellini; Kartik Viswanathan; Elizabeth C Finger; Anh N Diep; Edward L LaGory; Mihalis S Kariolis; Andy Chan; David Lindgren; Håkan Axelson; Yu R Miao; Adam J Krieg; Amato J Giaccia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-03       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.